Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil signs technology transfer deals worth $1.5 billion

This article was originally published in Scrip

Executive Summary

Pfizer, the Israeli firm Protalix and the Brazilian health ministry have signed a R$1.25 billion ($734 million) technology transfer deal that will see the state-owned pharmaceutical lab, Biomanguinhos, produce generic versions of Uplyso (taliglucerase alfa) for Gaucher's disease within five years.

You may also be interested in...



England’s NICE Recommends BMS/Celgene’s Revlimid For Follicular Lymphoma

Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.

Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council

The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.

Brazilian Regulator Approves New Advanced Therapy Regulations

Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.

Topics

Related Companies

UsernamePublicRestriction

Register

SC010427

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel